Global ADME-Toxicology Testing Markets 2016-2024: Strategic Business Report 2018 — Need for Better Models: A …


DUBLIN, July 12, 2018 /PRNewswire/ —

The “ADME-Toxicology Testing – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets.

This report analyzes the worldwide markets in US$ by the following Segments:

  • Toxicology Testing (In-Vivo, In-Vitro)
  • ADME Testing

The report profiles 69 companies including many key and niche players such as:

  • ACEA Biosciences, Inc. (USA)
  • ADMEcell, Inc. (USA)
  • Agilent Technologies, Inc. (USA)
  • Albany Molecular Research, Inc. (USA)
  • Beckman Coulter, Inc. (USA)
  • BioreclamationIVT, LLC (USA)
  • Cerep SA (France)
  • CompuDrug International, Inc. (USA)
  • Cyprotex PLC. (UK)
  • CeeTox, Inc. (USA)
  • Dassault Systmes Biovia Corp. (USA)
  • Eurofins ADME BIOANALYSES SAS (France)
  • Galapagos NV (Belgium)
  • Molecular Discovery Ltd. (UK)
  • MultiCASE, Inc. (USA)
  • Optivia Biotechnology (USA)
  • PerkinElmer, Inc. (USA)
  • Pharmaron, Inc. (USA)
  • Promega Corporation (USA)
  • Qualyst, Inc. (USA)
  • Simulations Plus, Inc. (USA)
  • Taconic Biosciences, Inc. (USA)
  • Takara Bio Europe AB (Sweden)
  • Tecan Group Ltd. (Switzerland)
  • Thermo Fisher Scientific, Inc. (USA)

Key Topics Covered

1. OUTLOOK

ADME-Tox Testing Gains Traction

A Peek into the Impact of ADME-Tox Screening on New Drug Discovery

Current and Future Analysis

US and Europe Dominate, Asia-Pacific Lends Growth Momentum

Growth Momentum Shifts Away from In Vivo Technologies; In Vitro Technologies to Lead the Charge

2. INDUSTRY OVERVIEW

Pharma Industry Renews Focus on Cost Optimization

China and India: Hot Spots for R&D Investment

ADME-Tox Assays

An Overview

Introduction of Early In Vitro ADMET Studies

Growing Prominence of Cell-based Assays in Drug Discovery and ADME Analysis

Major Types of Cell-Based HTS Assays for Drug Screening

CROs Expand Presence

Drug Discovery Outsourcing and Type of Services Outsourced

Changing Face of Drug Discovery Outsourcing Activity

M&A

Order of the Day

3. MARKET DYNAMICS

Current State of ADME-Tox Testing

Need for Better Models: A Major Factor Driving Innovation in the Market

Focus Shifts to Innovative Approaches

In Silico and In Vitro- the Way to Go

In Vitro Testing Systems and Its Relevance in Drug Development

In Silico ADME-Tox Growing at a Fast Clip

3-D Tissue Bioassays to Enhance In Vitro Toxicity Testing

Increasing Use of Cell-Based Assays over Other Methods in Toxicity Testing

Rising Number of Drug Targets Surge Demand for Cell-Based Assays

Growing Focus on the Development of Reproducible and Robust Cell-based Assays

Functional Assays: An Effective Way of Predicting Specific Toxic Effects

GPCR Targets to Drive Growth in Functional Cell Assay Market

New Alternatives for Early-Stage Toxicology Testing

Stem Cells Exude Great Potential in Drug Toxicity Testing

Primary Hepatocytes Become Standard Tool for Evaluation in Hepatic Metabolism

Improved Cryopreservation Technologies Help Expand Use of Hepatocytes

Cardiotoxicity Testing Gains Prominence

Cell Imaging-Gaining Popularity

In Vivo Imaging Persists in ADME-Tox Testing

Computational Models on Rise

Adoption of Data Management Systems

Drug Transporter Analysis Becoming Part of ADME Assessment

Slow Metabolism of Novel Drugs Call for More Human Models in Screening

Further Advances Required for More Understanding of Biotransformation

Introduction of Third Dimension in Cell Culturing Drives Need for New Instrumentation

Regulatory Bodies Focus on Transporter Mediated DDIs

4. DRUG DISCOVERY & DEVELOPMENT

Overview

Drug Discovery and Development

Target identification

Target Validation

Lead Identification

Lead Optimization

Pre-Clinical Testing

Clinical Trials

Drug Discovery Technologies

Innovation in Screening Guarantees Success for Drug Discovery Programs

5. PRODUCT OVERVIEW

6. PRODUCT INNOVATIONS/INTRODUCTIONS

Corning Adds Two New Products to ADME/Tox Lineup

Sovicell and 3B Pharmaceuticals Launch EScalate Assay Service

Lonza Launches Human and Animal Hepatocytes for Adme-Tox Testing

Cyprotex Launches Eight New Transporter Assays

Simulations Plus Rolls Out Version 8.0 of ADMET Predictor Software

Simulations Plus Launches Version 7.2 of ADMET Predictor Software

BioReliance Unveils Select In Vitro ADME and Toxicology Testing Services

Cyprotex Releases SenCeeTox Technology with Enhanced Capabilities

Cyprotex Expands In-House Drug Transporter Services

Cyprotex Launches KeratinoSens Service

Simulations Plus Introduces ADMET Predictor Version 7.1

Lena Biosciences Launches SeedEZ 3D Cell Culture Products

Sigma Life Science to Introduce Genetically-Modified HepaRG Human Liver Cell Line

7. RECENT INDUSTRY ACTIVITY

Simulations Plus to Take Over DILIsym Services

Simulations Plus and Electrolab India Sign Distribution Deal

Simulations Plus Inks Distribution Deal with Quantum Bio Solutions for Korean Market

Cyprotex Moves to New Location in the UK

Pharmaron Takes Over Xceleron

Evotec Acquires Cyprotex

Endonovo Expands Cytotronics Platform for Toxicology Testing

Takara Bio Acquires Cellectis AB

WuXi PharmaTech Acquires XenoBiotic Laboratories

Merck KGaA to Take Over Sigma-Aldrich

Dassault Systmes Acquires Accelrys

Organovo Collaborates with J&J for 3D Bioprinting Drug Discovery Research

Taconic and IVAL Enter into Agreement

Charles River to Acquire Galapagos’ Argenta and BioFocus Service Divisions

Simulations Plus Signs 5-Year RCA with the US FDA

Simulation Plus Inks Distributor Agreement with RILD

Harlan CRS Enters into Strategic Alliance with Bertin Pharma

Pharmaron Receives GLP Certification from the CFDA for GLP Toxicology Facilities

Cyprotex Acquires CeeTox

Taconic Announces Name Change

Rosa & Co. Acquires Entelos Holdings’ Consulting Service Business

Thermo Fisher Scientific Acquires Life Technologies

8. FOCUS ON SELECT PLAYERS

ACEA Biosciences, Inc. (USA)

ADMEcell, Inc. (USA)

Agilent Technologies, Inc. (USA)

Albany Molecular Research, Inc. (USA)

Beckman Coulter, Inc. (USA)

BioreclamationIVT, LLC (USA)

Cerep SA (France)

CompuDrug International, Inc. (USA)

Cyprotex PLC. (UK)

CeeTox, Inc. (USA)

Dassault Systmes Biovia Corp. (USA)

Eurofins ADME BIOANALYSES SAS (France)

Galapagos NV (Belgium)

Molecular Discovery Ltd. (UK)

MultiCASE, Inc. (USA)

Optivia Biotechnology (USA)

PerkinElmer, Inc. (USA)

Pharmaron, Inc. (USA)

Promega Corporation (USA)

Qualyst, Inc. (USA)

Simulations Plus, Inc. (USA)

Taconic Biosciences, Inc. (USA)

Takara Bio Europe AB (Sweden)

Tecan Group Ltd. (Switzerland)

Thermo Fisher Scientific, Inc. (USA)

9. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 69 (including Divisions/Subsidiaries 77)

  • The United States (46)
  • Canada (2)
  • Japan (1)
  • Europe (24)
    • France (4)
    • Germany (3)
    • The United Kingdom (6)
    • Spain (1)
    • Rest of Europe (10)
  • Asia-Pacific (Excluding Japan) (4)

For more information about this report visit https://www.researchandmarkets.com/research/mx5pgv/global?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com



Source link

Leave a Reply

Your email address will not be published.